Earnings Call - OMADA HEALTH INC

Financial Performance:

• Employer benefit costs are projected to rise 8.2% in 2027, marking the largest increase since 2003.
• 36% of employers experienced premium increases of 10% or more even after implementing significant plan changes.
• Pharmaceutical spending, specifically on GLP-1s, is a primary driver of rising costs, with 80% of employers citing GLP-1s as a cost driver.
• Omada's Markov-based micro-simulation model (based on 20,000+ members) projects healthcare savings of over $1,400 in Year 1, rising to over $4,700 by Year 3, and continuing to grow through Year 5 for members with high engagement and persistence.
• Digital programs can reduce costs by avoiding in-person visits for medication titration and side effect management.

Guidance and Future Outlook:

• The market is shifting from short-term cost avoidance to a long-term value equation focusing on durable outcomes over 2 to 5+ years.
• Future strategies must account for the complexity of managing multiple chronic conditions simultaneously rather than addressing diseases in isolation.
• Upcoming pricing dynamics for new GLP-1 formulations (e.g., oral, dual/triple agonists) are anticipated to evolve, though exact timelines for price reductions remain uncertain.
• Employers are advised to partner with solutions that can adapt to changing coverage landscapes, including supporting cash-pay members via Direct-to-Consumer (DTC) models if pharmacy benefits do not cover new medications.

Business Segments and Product Lines:

• Omada Health is emphasizing a holistic cardiometabolic care platform that integrates clinical support with lifestyle intervention, specifically targeting the 99 million Americans living with two or more chronic conditions.
• The company's "GLP-1 Investment Guide" utilizes a 5-year Markov-based model to demonstrate the clinical and economic value of combining medication persistence support with lifestyle changes.
• Product offerings include digital care coordination, real-time clinician access, and personalized lifestyle coaching to address medication adherence, side effects, and muscle retention.
• New focus areas include supporting patients who are ineligible for or opt out of medication through intensive lifestyle modification programs.

Market and Competitive Landscape:

• Market saturation of GLP-1 therapies and the introduction of new agents (oral formulations, dual/triple agonists like Retatrutide) are reshaping the treatment landscape.
• Current benefit design is often fragmented; 36% of employers see limited efficacy in traditional plan levers due to the inability to address the root causes of rising costs.
• A critical gap exists in the market regarding care coordination for patients with multiple comorbidities, where no single provider acts as a "quarterback" to reconcile conflicting guidelines.
• Competition involves navigating a "wild west" of DTC pricing and varying coverage levels, necessitating partners who can bridge gaps between health plans, PBMs, and cash-pay options.

Risks and Challenges:

• "Concentration risk": Less than 1% of members drive over one-third of spend, often due to complex, multi-condition cases that standard condition-specific programs fail to address.
• Fragmentation of care leads to polypharmacy, drug interactions, and poor adherence, particularly when patients act as their own care coordinators.
• Access barriers, such as Medicare Part D "donut holes" or benefit exclusions, can cause medication lapses that require rapid clinical adaptation to prevent health deterioration.
• The risk of "information overload" for patients, where support tools add complexity rather than simplifying the care journey.

Management Commentary and Tone:

• Management (Kevin Massey, Dr. Rajiv Roy, Britt Brutman) maintained a professional, empathetic, and highly collaborative tone, focusing on patient-centered solutions.
• There was strong emphasis on moving beyond binary "coverage decisions" to holistic care strategies that prioritize patient outcomes and long-term value.
• Speakers expressed confidence in the necessity of integrating lifestyle support with pharmacotherapy, noting that medication alone is insufficient without behavioral reinforcement.
• The tone reflected a deep understanding of employer constraints, acknowledging the pressure of rising costs while advocating for value-based care models.

Analyst Questions and Answers:

• Q: How should 2027 plans evolve with new GLP-1 options and pricing?
  • A: Employers should partner with evidence-based clinical providers who can navigate the latest formulations and utilize DTC models to support members if pharmacy coverage is unavailable.
• Q: Do engagement requirements improve outcomes or create hurdles?
  • A: Data indicates that linking medication access to lifestyle engagement (e.g., coaching, behavior tracking) correlates with better persistence and outcomes; patients often view this support as valuable rather than burdensome.
• Q: How to support patients not wanting or unable to take GLP-1s?
  • A: Focus on intensive lifestyle modifications and alternative medications; clinical guidance remains essential to ensure non-pharmaceutical approaches are effective.
• Q: When will GLP-1 prices decrease due to market saturation?
  • A: Prices have already declined slightly as new drugs enter the market, but significant drops depend on the competitive landscape of upcoming agents (e.g., Retatrutide); however, even marginal differences in weight loss efficacy (e.g., 21% vs. 23%) provide significant clinical value.

Other Key Points:

• The "Michael" Persona: The call highlighted a hypothetical patient (Michael, 52) with diabetes, obesity, hypertension, and arthritis to illustrate the failure of siloed, condition-by-condition care management.
• Three Principles of Care: Effective programs must provide (1) meaningful agency and choice with clinical guidance, (2) personalized and timely guidance, and (3) adaptable support that fits into real-life changes without adding burden.
• Value Metrics: Key indicators for success include medication persistence (67% improvement seen in Omada programs), program engagement (22% increase in lifestyle changes), and downstream clinical outcomes (A1C, BP, weight) leading to cost savings.
• Call to Action: Benefits leaders are urged to demand transparent data on outcomes and cost projections, rather than relying on marketing claims, to validate the value of digital health partners.